How to Ask Your Doctor for HRT

The HRT Index Editorial TeamIndependent women's health research

Last reviewed:August 26, 2026

Editorial research — not medically reviewed by a clinician. Why this label

Last updated: August 26, 2026 · Last verified: August 26, 2026 · By The HRT Index Editorial Team. Educational research, not medical advice, and not reviewed by a clinician. See our medical review policy. Full disclosure.

Go into the appointment with a plan

Match your symptoms, age, uterus status, risk history, insurance, state, and route preference before choosing a clinician or online care.

Find My HRT Path

Here’s how to ask your doctor for HRT: “I’d like to talk about treatment for my menopause symptoms today, including hormone therapy. The two worst are ___ and ___, and they’re affecting ___.” Then ask: “Based on my history, am I a candidate—and if not, what’s the specific reason?” Leave with treatment, testing, an alternative, or a referral.

Here is what changes the answer. The current systemic labels checked for this page—Divigel and Bijuva—list conditions such as undiagnosed abnormal genital bleeding, a personal history of breast cancer, estrogen-dependent cancer, active or past blood clots, stroke or heart attack, liver impairment or disease, and known clotting disorders as contraindications. Starting systemic therapy after age 60 or more than 10 years after menopause onset calls for a more individual risk review. Pregnancy can still happen during perimenopause, and menopausal hormone therapy is not birth control.

But here is the part nobody tells you before you walk in: a documented reason many women hit a vague no has nothing to do with saying the wrong words. Menopause training gaps are real. Once you see the numbers, you can stop treating every brush-off as a verdict on your symptoms—and start asking the question that forces the visit toward a plan.

The first 60 seconds, in three moves

Move	What to say or bring	What it should produce
Say	Your two worst symptoms, roughly when they started, and what they are wrecking—sleep, work, sex, concentration, or daily life	A clear treatment target
Ask	“Based on my history, am I a candidate for hormone therapy—and if not, what’s the specific reason?”	A clinical reason, not a shrug
Leave with	Treatment, testing, an alternative, or a referral	A defined next step with a date

Best for: You have an appointment booked, you were dismissed once and are preparing for round two, or you know you want to discuss treatment and do not know how to say it out loud.

Not for you if: You are looking for magic words that force a prescription. Those words do not exist, and they should not. This page also does not cover gender-affirming hormone therapy. If you have bleeding after menopause, new or unusually heavy bleeding, possible pregnancy, or severe rapidly worsening symptoms, skip the script and get evaluated.

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

How to ask your doctor for HRT: the four-sentence script

Answer capsule: Open with treatment rather than a demand for one drug. Name your two worst symptoms, attach the damage they are doing, hand over a short written record, and ask whether you are a candidate. If the answer is no, ask for the specific reason and the next plan.

Four sentences. That is the whole opening. The order is doing real work.

Sentence 1 — Name the ask without turning it into a demand

“I’d like to talk about treatment for my menopause symptoms today, including hormone therapy.”

Why this works: hormone therapy is one option inside a treatment conversation. You are not asking the clinician to surrender clinical judgment. You are making clear that symptom treatment is the purpose of the visit and that HRT belongs in the discussion.

Compare it with: “I want to get on HRT.” Same goal. Completely different room.

Sentence 2 — Name two symptoms and attach the damage

“The two worst are waking up drenched three or four times a night and brain fog bad enough that I’m rereading emails five times. It’s hitting my work and my marriage.”

“Hot flashes” is a symptom. “Waking four times a night and falling asleep at my desk” shows severity and function.

Two or three symptoms. Not fourteen. A long inventory can bury the two problems you need addressed first. Rank them.

Sentence 3 — Show the pattern instead of rebuilding it from memory

“I wrote down when it happens and what it interrupts—here.”

A short record gives the clinician dates, frequency, and impact without making you narrate the last six months under pressure. It also protects you from forgetting the one detail you promised yourself you would say.

Sentence 4 — Ask the question that requires a reason

“Based on my history, am I a candidate—and if not, what’s the specific reason?”

“Can I have HRT?” invites yes or no. “Am I a candidate, and if not, why?” asks the clinician to name the reason.

That reason is portable. It tells you whether the issue is a safety condition in your chart, an evaluation that needs to happen first, a better treatment for the symptom you actually have, or a clinician who does not manage menopause care.

If you only have 15 seconds

“I want to use today to decide whether hormone therapy fits my symptoms and my history. If it doesn’t, I want to understand why and what the next best option is.”

Say this, not that

Instead of this	Say this
“I need the patch. It’s the safest.”	“Can we compare the routes and talk about which one fits my history?”
“My hormones are low.”	“These symptoms started around ___, happen ___, and are affecting ___.”
“I know I’m in perimenopause.”	“Could perimenopause explain this? What else should we rule out?”
“I want bioidentical hormones.”	“Is the exact product you’re suggesting FDA-approved or compounded, and why that one?”
“Just give me HRT.”	“Can we decide together whether it fits—and what the alternatives are if it doesn’t?”
A symptom you do not have	The symptoms you actually have

That last row is not filler. Advice circulates online telling women to claim hot flashes because vasomotor symptoms are a familiar HRT indication. Do not do that. Hot flashes, vaginal dryness, painful sex, heavy bleeding, low mood, and sleep disruption do not all point toward the same treatment. A false symptom can send the visit toward a prescription that never touches the problem you came to solve.

The one thing this page cannot do for you

Here is the honest part, and we would rather you hear it here than discover it in the room.

A script cannot make an unwilling doctor willing, and it should not. If the hesitation is a real safety issue in your chart, no sentence should override it. If the hesitation is a training or scope gap, four sentences cannot install missing menopause education during a fifteen-minute visit.

What the script can do is get you a reason instead of a shrug. That is a smaller promise and a far more useful one, because every path forward starts with knowing which kind of no you received.

Redefine the win now. A good appointment does not have to end with a prescription. It should end with one of four plans:

A treatment plan.
A testing or evaluation plan.
An alternative-treatment plan.
A referral.

Three of those four do not require your doctor to say yes today. All four move you forward. “Let’s see how it goes” without a next action or review date is the outcome to refuse.

The right online HRT provider is not the same for every woman—it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer cannot resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider—and to flag when online care is not the right starting point—before your first consult.
→ Match my situation before I book
About 90 seconds. No email needed. A licensed clinician makes every treatment decision.

What should I bring to the appointment?

Answer capsule: Bring one page, not a folder. Put your goal, top symptoms and functional impact, rough timeline, cycle and bleeding pattern, uterus and ovary status, current medicines, relevant history, pregnancy possibility, and one question you will not leave without answering on that page. Bring what you have; do not delay care to build a perfect diary.

Seven blocks. One page. That is enough.

1. Your goal for the visit

Write one sentence at the top:

“Find out whether hormone therapy fits me—and if not, what does.”

That line keeps the visit from drifting into a general physical while the thing that brought you there disappears.

2. Your top two or three symptoms

Rank the real ones. Add what each is costing you.

Night sweats: waking three or four times a night; missing morning workouts.
Vaginal dryness: pain during sex; avoiding intimacy.
Brain fog: repeating work and missing details.
Hot flashes: six to eight episodes during the workday.
Mood change: new irritability or anxiety affecting home life.

Do not copy a list from the internet and circle everything. Your actual pattern is more useful than a complete symptom encyclopedia.

3. Roughly when it started and how it behaves

“Last spring.” “Worse the week before my period.” “Every night since June.” “Comes in clusters.”

Approximate is fine. The point is pattern, not courtroom precision.

4. Your cycle and bleeding history

Write down:

When your periods began changing.
The date of your last period, if you know it.
Whether bleeding is new, unusually heavy, prolonged, after sex, or after menopause.
Whether you have had a hysterectomy, endometrial ablation, or an IUD.
Whether pregnancy is possible.

A hysterectomy, ablation, or hormonal IUD can make menstrual history harder to interpret. That does not erase the symptoms; it changes what information the clinician uses.

5. Whether you still have a uterus—and what surgery removed

If you have an intact uterus and use systemic estrogen, protecting the uterine lining generally becomes part of the plan. That often means a progestogen, but the exact approach depends on the product and regimen.

If you do not know whether your cervix, uterus, or ovaries were removed, write “not sure”. That is a normal thing not to know. Ask the clinician to check the operative record.

6. Medicines, supplements, allergies, and the history that changes the decision

Bring a current list with doses—or bring the bottles. Include any history of:

Blood clot, deep vein thrombosis, or pulmonary embolism.
Stroke or heart attack.
Breast cancer or another estrogen-dependent cancer.
Liver impairment or disease.
Known clotting disorder.
Unexplained genital bleeding.
Migraine pattern.
High blood pressure.
Gallbladder disease.
Seizure history.
Current tobacco use.
Pregnancy or possible pregnancy.

Not every item is an automatic no. Some are listed contraindications on specific labels; others change route, product, monitoring, or counseling.

7. The question you will not leave without answering

Default:

“If hormone therapy is not the plan, what specifically is—and when do we review it?”

How long should I track symptoms before I go?

Do not delay a booked appointment to build a perfect diary.

Two or three weeks of notes can help. So can two days. So can writing the pattern down the night before from memory. Bring what exists now. Improve the record later if the decision remains unclear.

For a fuller inventory, use the perimenopause symptoms checklist.

The HRT Appointment Prep Matrix

This is the one-page structure we use because every line answers a decision question the clinician is already working through.

Block on your page	What to write	Decision it helps resolve
Goal	“Decide whether HRT fits and what the backup is.”	Keeps the visit on treatment
Top symptoms	Two or three, ranked	Defines the treatment target
Functional cost	Sleep, work, sex, mood, exercise, caregiving	Shows severity without exaggeration
Timeline and pattern	Start date, frequency, cycle relationship	Helps separate a transition pattern from another cause
Bleeding and pregnancy	Last period, new/heavy/postmenopausal bleeding, pregnancy possibility	Flags evaluation and contraception questions
Anatomy	Uterus present/absent/unsure; ovaries present/absent/unsure	Determines whether endometrial protection belongs in the plan
Medicines and history	Medication list plus clot, cancer, liver, cardiovascular, migraine, seizure history	Screens for label restrictions, interactions, and route choices
One non-negotiable question	“If not HRT, what is the reason and next step?”	Prevents a dead-end visit

Three practical moves before the visit

When scheduling, say: “I need to discuss menopause symptoms and treatment options.” Ask whether a longer slot is available.
Bring a notepad. If you want to record audio, ask first and follow the law where you are.
Bring a support person when that will help you remember details or speak up. Tell the office in advance if the visit is virtual or the practice has guest rules.

Why is this conversation harder than it should be?

Answer capsule: Menopause training gaps are documented, but this survey is not a national denial rate. In a 2019 multicenter resident survey, only 6.8% felt adequately prepared, 20.3% had received no menopause lectures, and 34.4% would not offer hormone therapy to a straightforward candidate. Its 26% response rate shows a gap—not what your doctor will do.

Researchers sent surveys to 703 family medicine, internal medicine, and OB-GYN residents at 20 U.S. programs. A total of 183 responded.

Among those respondents:

93.8% said menopause-management training was important.
20.3% reported receiving no menopause lectures during residency.
6.8% felt adequately prepared to manage menopause.
34.4% said they would not offer hormone therapy to a symptomatic, newly menopausal woman with no contraindications.

Those numbers come from a peer-reviewed cross-sectional study in Mayo Clinic Proceedings. The response rate was 26%, and the respondents were doctors in training—not every U.S. clinician. The study does not prove why your doctor said no. It proves that a measurable education gap existed across the participating programs. (Kling et al., 2019)

Read the 34.4% again. In that sample, about one in three would not offer hormone therapy to the uncomplicated patient described in the survey. That is not your chart failing a test. It is a reason to ask for the clinical reason instead of assuming the problem was how you spoke.

The gap also appears in appointment data

A separate research team examined electronic health records for 5,491 women aged 40 to 55 with an outpatient encounter tied to a menopause-related code. The results were presented at The Menopause Society’s 2025 annual meeting:

Specialty seen	Share of encounters
OB-GYN	64.4%
Internal medicine	17.6%
Family medicine	12.4%
Endocrinology	4.5%

Only 17.1% received prescription treatment for menopause symptoms in that dataset. Among those treated, 34% received systemic estrogen, 47% vaginal estrogen, and 16% an SSRI. Patients seen by OB-GYN clinicians were most likely to receive systemic estrogen; internal and family medicine visits were more likely to result in an SSRI. (The Menopause Society, 2025)

This was a conference presentation, not a peer-reviewed full publication. It came from one electronic-record analysis, not a national probability calculator. The accurate takeaway is narrower and still brutal: in that dataset, 82.9% had no prescription treatment linked to the menopause encounter.

That is why preparation can change the shape of the visit. When time and experience are uneven, an organized patient who names the treatment target and asks for a reason makes it harder for the conversation to dissolve into “come back if it gets worse.”

What is my doctor actually deciding?

Answer capsule: Your clinician is matching the symptom to a treatment, then checking age and timing, bleeding and pregnancy possibility, whether you have a uterus, personal and family history, medicines and interactions, and the route and product that fit. A single hormone level is not a yes-or-no switch, but several items in that sequence can change or rule out systemic treatment.

Knowing what is running through the clinician’s head lets you hand over the right information in the first two minutes.

Which symptom is being treated?

Hot flashes and night sweats are vasomotor symptoms. Vaginal dryness, burning, painful sex, and some urinary symptoms point toward genitourinary treatment, which may be local rather than systemic. Sleep, mood, joint pain, fatigue, and cognitive complaints can overlap with menopause and with other conditions.

This is why naming the real symptom beats reciting a list. The treatment target comes first.

How old are you, and how long has it been since menopause began?

The Menopause Society’s 2022 position statement describes the benefit-risk balance as generally favorable for healthy women with bothersome symptoms who are younger than 60 or within 10 years of menopause onset, assuming no contraindications. Starting systemic therapy later is not a universal ban, but the absolute risks of coronary disease, stroke, venous thromboembolism, and dementia are higher and the decision becomes more individual. (The Menopause Society 2022 position statement)

Do not turn that into “under 60 means safe” or “over 60 means impossible.” It means timing is one input, not the entire decision.

What is happening with bleeding, periods, and pregnancy possibility?

Perimenopause happens while periods are still occurring. You do not have to wait for twelve months without a period to discuss treatment.

New, unusually heavy, prolonged, postcoital, unexplained, or postmenopausal bleeding may need evaluation before or alongside treatment. Pregnancy is still possible during perimenopause. Menopausal hormone therapy does not replace contraception.

Do you still have a uterus?

If yes, and systemic estrogen is being considered, protection against endometrial overgrowth generally belongs in the plan. Depending on the product, that may be a separate progestogen or an approved combination therapy.

“Everyone needs progesterone” is wrong. “No one needs progesterone” is wrong. Ask what applies to the exact product, route, and anatomy in front of you.

What does your history change?

This is where a real no can come from: prior breast cancer, estrogen-dependent cancer, clotting events, stroke, heart attack, liver disease, unexplained bleeding, a known thrombophilia, or a product allergy. Other conditions may change route, dose, monitoring, or specialist involvement without being a label contraindication.

Can the plan be obtained and followed?

Only after clinical fit comes the practical layer: cost, insurance, pharmacy stock, lab access, follow-up, and whether the exact medication is FDA-approved or compounded. A plan you cannot obtain, afford, or monitor is not a completed plan.

Am I even a candidate for HRT?

Answer capsule: There is no universal online eligibility list because labels differ by product and your chart matters. Current February 2026 FDA labels for Divigel and Bijuva list undiagnosed abnormal genital bleeding, breast cancer history, estrogen-dependent neoplasia, past or active blood clots, past or active stroke or heart attack, liver impairment or disease, known thrombophilias, and serious product hypersensitivity as contraindications.

We want you to know the boundary before the appointment, because it is the difference between asking for a clearer explanation and trying to argue past a safety condition.

What current FDA labels actually list

The table below is a direct cross-check of the Contraindications sections in the February 2026 FDA labels for Divigel (systemic estradiol gel) and Bijuva (oral estradiol plus progesterone). The exact list for another product can differ, so the prescribed label still controls.

Contraindication in both checked labels	What it means for the conversation
Undiagnosed abnormal genital bleeding	Ask for the workup and timeline, not a way around it
Breast cancer or a history of breast cancer	Do not push for systemic treatment past the label; ask about specialist-guided alternatives
Estrogen-dependent neoplasia	Ask what non-estrogen or specialist options remain
Active deep vein thrombosis or pulmonary embolism, or a history of either	A label-level stop for these products
Active arterial thromboembolic disease such as stroke or heart attack, or a history of either	A label-level stop for these products
Hepatic impairment or disease	A label-level stop for these products
Protein C, protein S, or antithrombin deficiency, or another known thrombophilic disorder	A label-level stop for these products
Anaphylactic reaction, angioedema, or hypersensitivity to the product	The exact product matters

Source: Divigel prescribing information, revised February 2026 and Bijuva prescribing information, revised February 2026.

Pregnancy is not in the Contraindications section of either current label checked above. Both products are not indicated for use during pregnancy. That distinction does not make pregnancy a routine HRT situation; it means possible pregnancy needs to be said out loud and evaluated instead of being misquoted as an item on these two contraindication lists.

What is not automatically a label-level no

Often treated as an automatic no	What the checked labels support
A family history of breast cancer	Family history is not listed as a contraindication in the checked labels. It can still change individualized risk assessment, genetic questions, screening, and counseling.
Still having periods	Perimenopause occurs before the final period. Ongoing cycles affect regimen, bleeding expectations, and contraception—not whether symptoms deserve treatment.
High blood pressure by itself	Not listed as a contraindication in the checked labels. It still belongs in cardiovascular risk assessment and should be managed.
Higher body weight	Not listed as a contraindication. It can affect baseline clot and cardiovascular risk and therefore the route discussion.
Fibroids	Not listed as a contraindication. Bleeding pattern and fibroid-related symptoms still matter.
Being younger than the usual menopause age	Younger age is not itself a contraindication. Symptoms before 45—and especially before 40—deserve evaluation for early or premature menopause and other causes.
Being over 60	Age alone is not on the contraindication list. Starting systemic therapy later changes the benefit-risk discussion.

Use this table to follow the conversation, not to declare yourself eligible. Your clinician has your full history. This page does not.

If a label-level red row describes you

Do not use population-level reassurance to argue past a personal contraindication. “But the FDA changed the boxed warning” does not erase a past clot, stroke, heart attack, breast cancer history, liver disease, or unexplained bleeding.

Ask instead:

“Given this part of my history, what options are still open—and should a menopause specialist, gynecologist, oncologist, hematologist, or other clinician be involved?”

Low-dose local vaginal therapy, nonhormonal prescription treatment, and symptom-specific care are separate conversations. Do not assume local estrogen is automatically cleared: exposure is different, but exact product labeling and your cancer, clotting, or bleeding history still need clinician review.

Do I need blood tests before I can get HRT?

Answer capsule: Usually, a typical menopause transition can be assessed from age, symptoms, and menstrual history without a hormone panel. FSH and estradiol fluctuate enough to make one result hard to interpret. Testing becomes more useful when symptoms start before 45, the pattern is atypical, pregnancy or another diagnosis is possible, or cycles cannot be used as a marker.

“Let’s check your hormone levels first” is one of the most common turns in this conversation. Sometimes it is exactly right. Sometimes the result will not change the treatment decision.

NIH’s 2026 menopause research overview says age, menstrual history, and symptoms are typically sufficient for diagnosis and that laboratory testing is not usually necessary. It also notes that FSH and estradiol can be highly variable across the cycle. (NIH DiscoverWHR, updated June 2026)

When testing can genuinely help

Testing is useful when the result answers a real question:

Symptoms begin before age 45, especially before 40.
Pregnancy is possible.
The pattern is atypical or another diagnosis is plausible.
Thyroid disease, anemia, or another cause could explain part of the picture.
Menstrual history cannot be used cleanly after hysterectomy, ablation, or with some hormonal contraception.
A medication requires baseline or follow-up labs, as with certain nonhormonal prescriptions or testosterone.
The clinician is checking a specific safety issue, not trying to reduce the entire decision to one estrogen number.

The one question to ask before the blood draw

“What question will this test answer, and how will each possible result change the plan?”

Then ask the sharper version:

“If the hormone result comes back in the normal range, does that rule out treating the symptoms?”

A normal result does not prove your symptoms are imaginary. It also does not prove hormone therapy is right. It is one piece of a decision with several pieces.

What will my doctor say—and what do I say back?

Answer capsule: Most hesitations fall into three groups: a condition that appears in current product labeling, a legitimate judgment that depends on your symptoms and history, or a statement that needs a specific clinical reason. The response decoder below does not tell you to win an argument. It tells you which question converts the answer into a safe next step.

This is the part of the page we built first and checked hardest.

We matched thirteen commonly reported responses against current FDA labeling, the FDA’s 2026 product-specific relabeling, The Menopause Society’s current position statements, NIH diagnostic guidance, and current drug and payer documents.

The classification is The HRT Index’s editorial framework. The source facts are linked so you can check them.

🔴 Label or safety stop: Do not push past it. Ask what remains open.
🟠 Real clinical decision: Your specifics determine the answer.
🟡 Needs a specific reason: A blanket statement is not enough to close the question.

The Doctor Response Decoder

What you hear	Status	What the current evidence or label supports	What to say next
“You’re too young for menopause.”	🟡	Symptoms before 45 can call for more evaluation; younger age does not make the symptoms disappear. Early and premature menopause are real clinical situations.	“What are you evaluating because of my age, and what symptom treatment is available while we do that?”
“Wait until your periods stop.”	🟡	Perimenopause occurs while cycles continue. Twelve months without a period is not a prerequisite for discussing treatment.	“Is there a clinical reason to wait in my case, or is that a general rule? The symptoms are happening now.”
“HRT causes breast cancer.”	🟠	Risk depends on the regimen, duration, baseline risk, and exact product. The FDA removed breast-cancer language from the boxed warning of six products in February 2026, but malignancy warnings and individual counseling did not disappear.	“I’m not asking you to ignore risk. What does the risk look like for my history and the exact regimen you would consider?”
“Let’s check your hormone levels first.”	🟠	Testing may answer a real question, but one FSH or estradiol result usually does not settle a typical transition because levels fluctuate.	“What question will the test answer, and how will a normal or abnormal result change the plan?”
“You’re not having hot flashes.”	🟠	Hormone therapy is not a universal answer for every symptom. Vaginal and urinary symptoms may call for local treatment; other symptoms may need another diagnosis or treatment target.	“Which of my actual symptoms can we treat? If they’re mainly vaginal or urinary, should we compare local and systemic options?”
“Let’s try an antidepressant instead.”	🟠	Some SSRIs and SNRIs are evidence-supported nonhormonal options for vasomotor symptoms, and they may also fit a mood disorder. That does not answer whether HRT is inappropriate for you.	“I’m open to that. Before we choose it, am I a candidate for hormone therapy—and if not, what is the specific reason?”
“Let’s use a nonhormonal menopause drug instead.”	🟠	Fezolinetant and elinzanetant are FDA-approved for moderate-to-severe vasomotor symptoms. They have their own liver-testing, interaction, pregnancy, sedation, and seizure considerations.	“Why does this fit my history better, what monitoring does it require, and will my plan require prior authorization?”
“You’re over 60” or “It’s been too long.”	🟠	Starting systemic therapy after 60 or more than 10 years from menopause onset generally has a less favorable benefit-risk balance. It is an individual decision, not a one-line age ban.	“Which risks are driving the decision in my chart, and what symptom-specific options remain?”
“You have a family history of breast cancer.”	🟠	Family history is not in the Contraindications section of the current Divigel or Bijuva labels. It can still change screening, genetic assessment, and counseling.	“Are you treating this as a contraindication or as a risk factor we weigh? What part of the family history changes the plan?”
“You’ve had a blood clot” or “You have a clotting disorder.”	🔴	Active or past DVT/PE and known thrombophilic disorders are contraindications in the checked systemic labels.	“Given that, what nonhormonal or specialist-guided options are appropriate for my symptoms?”
“You have unexplained bleeding.”	🔴	Undiagnosed abnormal genital bleeding is a listed contraindication and requires evaluation.	“What workup is needed, how soon can it start, and what happens after the result?”
“I don’t prescribe HRT” or “We don’t manage that here.”	🟡	This is a scope answer, not a medical verdict about you. Menopause training and prescribing patterns vary.	“Could you refer me to someone who routinely manages menopause and put the referral question in my visit summary?”
“It only masks menopause—you’ll go through it later.”	🟡	Hormone therapy treats symptoms; it does not pause ovarian aging. Symptoms may return after stopping, which is a review and discontinuation-plan question.	“Then let’s include the exit plan. When would we reassess, and what would stopping or tapering look like?”

Some rows are not negotiable

We would rather lose your click than help you argue with a clinician who is protecting you.

A past or active blood clot, stroke or heart attack, a personal history of breast cancer or another estrogen-dependent cancer, a known clotting disorder, undiagnosed abnormal bleeding, or liver impairment or disease appears as a contraindication in the current systemic labels checked for this page.

Do not shop for someone who will ignore the fact. Ask what symptom treatment is still available, whether another specialty should be involved, and what evidence would change the decision.

Does a red row describe your situation?
The question is no longer “How do I ask harder?” It is “What remains open?” Find My HRT Path separates systemic, local, nonhormonal, FDA-approved, and compounded routes and flags when in-person care should come first.
→ See which starting paths still fit my situation

Did the FDA remove the HRT boxed warning in 2026?

Answer capsule: Partly—and product by product. On February 12, 2026, the FDA approved labeling changes for six named menopausal hormone therapy products. Cardiovascular disease, breast cancer, and probable dementia language was removed from those boxed warnings. The action was not a completed class-wide rewrite, and contraindications and other warnings remained in the individual labels.

On November 10, 2025, HHS and the FDA announced the relabeling initiative. Twenty-nine companies submitted proposed changes. On February 12, 2026, the FDA approved the first six products across four therapy categories. (FDA press release)

The six products on the FDA’s current list

Therapy category	Product with updated prescribing information
Progestogen alone	Prometrium
Systemic estrogen alone	Divigel
Systemic estrogen alone	Cenestin
Systemic estrogen alone	Enjuvia
Topical vaginal estrogen	Estring
Systemic estrogen plus progestogen	Bijuva

Source: FDA list of menopausal hormone therapies with updated prescribing information.

What changed—and what did not

Cardiovascular disease, breast cancer, and probable dementia language came out of the boxed warning for the six listed products.
The action did not make every menopausal hormone product’s label identical.
Current product labels still contain contraindications, warnings, precautions, adverse reactions, and regimen-specific counseling.
The endometrial-cancer boxed warning remains on systemic estrogen-alone treatment for women with a uterus. The February 2026 Divigel label shows that warning and records the removal of the other boxed-warning topics.
The February 2026 Bijuva label records removal of its boxed warning and retains its contraindications and warnings-and-precautions sections.

The Menopause Society supported removal of the boxed warning for low-dose vaginal estrogen and said systemic estrogen still has potential risks in certain individuals that need detailed review when therapy starts. Its statement was published November 10, 2025. (The Menopause Society)

The sentence that will land better in the appointment

Do not say:

“The FDA removed the black box warning from all HRT.”

Say:

“I know the FDA approved product-specific label changes in February 2026. Which exact product are you considering, and what does its current label say for someone with my history?”

That sentence is accurate. It also gets you the exact drug name you need for the cost, route, contraindication, and pharmacy conversation.

What if my doctor says no?

Answer capsule: Ask for the specific reason before you leave and ask for the next step in your visit summary. A no usually functions as one of four things: a safety stop, an evaluation-first plan, an alternative-first plan, or a scope limit. Each needs a different response. Only a scope limit automatically means finding another clinician.

Do not argue. Do not leave yet. Ask which kind of no it is.

“I want to understand the reason. Is the concern something specific in my history, something you need to evaluate first, a different treatment that fits better—or is menopause care outside what you manage?”

That question sorts the room.

The four kinds of no

1. A safety no

Something in your history makes the requested treatment inappropriate or conflicts with the exact product label.

Your next move: alternatives and, when needed, specialist input—not a search for someone who will ignore the same history.

Ask:

“What is still appropriate for the symptom I need treated, and which specialist should be involved?”

2. An evaluation-first no

Bleeding, possible pregnancy, an atypical symptom pattern, or another diagnosis needs to be checked.

Your next move: a time-bounded workup.

Ask:

“What are you evaluating, what does each result change, and when do we make the treatment decision?”

3. An alternative-first no

The clinician believes another treatment fits your symptom or history better.

Your next move: define the trial.

Ask:

“What symptom are we targeting, how long is the trial, what counts as success, and when do we revisit HRT?”

4. A scope no

The clinician does not routinely manage menopause treatment.

Your next move: a referral or a second-opinion appointment with someone who does.

Ask:

“Could you refer me to a clinician who manages menopause and include the reason for referral in my visit summary?”

Do not assume every no is a scope no. Make the clinician name the category.

Ask for it in writing—the calm version

“Could you put the reason and the recommended next step in my visit summary so I can follow the plan accurately?”

That is a records request, not a threat.

Avoid “make them put the refusal in writing.” Avoid threatening a complaint in the room. If you want to record the visit, ask permission first and follow local law. The goal is a usable record and a next step, not an adversarial performance.

A documented reason matters for two reasons:

It follows you to the next clinician, so you do not start from zero.
It may supply the exact evidence an insurer requests for another treatment.

For example, UnitedHealthcare’s commercial prior-authorization policy effective May 15, 2026, requires a diagnosis of moderate-to-severe vasomotor symptoms plus a documented 30-day failure, contraindication, or intolerance to either hormonal therapy or an older nonhormonal option before Lynkuet or Veozah approval, along with baseline liver testing. That is one insurer’s policy—not a universal rule—but it shows why chart documentation can matter. (UnitedHealthcare policy)

The five-day plan after a scope no

Day	Do this
Day 0	Ask for the reason and referral in the visit summary
Day 1	Read the note and match it to the four kinds of no
Day 2	Search The Menopause Society directory by ZIP code or telehealth state
Day 3	Book the second-opinion or referral visit
Day 5	Bring the same one-page sheet plus the first clinician’s documented reason

Second opinions are normal

You may need permission to hear this more than you needed permission to ask for HRT.

A second opinion is reasonable when the explanation stayed vague, the clinician said menopause care was outside their scope, symptoms remain disruptive after a fair trial, or your history is complicated enough to deserve specialty input.

The second opinion may reach the same conclusion. That is not a wasted visit. It is a confirmed answer, and you can stop wondering whether the first no was medicine or discomfort.

What should I leave the appointment with?

Answer capsule: Leave with one defined plan, not “we’ll see.” A successful appointment ends in treatment with a follow-up date, an evaluation plan with a timeline, an alternative trial with success criteria, or a referral with a specific question. Three of those four outcomes do not require a hormone prescription that day.

Use this as the exit standard.

Outcome	What you need before you walk out
Treatment plan	Exact product, route, treatment target, directions, major risks and common side effects, expected bleeding, pharmacy or fulfillment step, cost question, and review date
Evaluation plan	What is being evaluated, tests or records needed, how results change the decision, and a timeline
Alternative plan	Target symptom, why this option fits, trial length, success measure, side effects or monitoring, and reassessment date
Referral plan	Type of clinician, urgency, records to send, what to do while waiting, and the exact question the referral should answer

Say the plan back

“Let me make sure I have it: the plan is ___, I should contact you sooner if ___, and we will review it by ___.”

That is teach-back. It catches misunderstandings while you are still in the room.

Who can prescribe HRT—and how do I find someone who manages it?

Answer capsule: Physicians, nurse practitioners, physician assistants, and certified nurse-midwives may prescribe menopause hormone therapy when their state license, scope, supervision rules, and practice permit it. A menopause credential can signal focused training but does not itself create prescribing authority. Experience varies, so ask what the clinician routinely manages before booking.

The accurate question is not “Can this profession ever prescribe?” It is “Can this clinician prescribe in my state and within this practice—and do they routinely manage menopause?”

Clinician route	Can prescribe?	What the current evidence says	Best use
OB-GYN	Generally yes, within licensure and practice	In the 2025 conference dataset, OB-GYN encounters were most likely to result in systemic estrogen	Strong default when bleeding, pelvic symptoms, or gynecologic history are central
Primary care or family medicine	Physicians generally yes; NP/PA authority depends on state and practice	Prescribing patterns vary; family medicine encounters in the dataset were more likely to result in SSRIs than systemic estrogen	Good when you have an established clinician who listens and manages the whole chart
Internal medicine	Physicians generally yes; NP/PA authority depends on state and practice	Same dataset showed a lower systemic-estrogen pattern than OB-GYN	Good for a complex medical history and coordinated chronic care
Endocrinology	Generally yes	A small share of the menopause-coded encounters in the dataset; not automatically the first menopause stop	Useful when thyroid, pituitary, metabolic, or premature-ovarian-insufficiency questions dominate
The Menopause Society Certified Practitioner (MSCP)	Only if the holder’s underlying license permits prescribing	The credential is earned by passing a menopause competency examination; it is not a medical license	Useful as a menopause-training signal after a vague or scope-based no
Telehealth clinician	Yes when licensed for the patient’s state and practicing within scope	Access depends on state licensure, company model, and the individual clinician	Useful when local access is slow or the first clinician does not manage menopause

The specialty numbers above come from a 2025 annual-meeting presentation, not a peer-reviewed national study. They show a pattern in that dataset, not a guarantee about the clinician you book.

How to use The Menopause Society directory

The directory can be searched by country, U.S. ZIP code, or telehealth availability by state. It includes Society members and MSCPs who asked to be listed; clinicians not accepting new patients are excluded. The directory says it is not complete. (The Menopause Society practitioner directory)

MSCP means the clinician passed The Menopause Society’s competency examination. All licensed healthcare professionals may be eligible to sit the exam, but the credential does not turn a nonprescriber into a prescriber and does not replace checking licensure, scope, and fit. (MSCP credential requirements)

Ask these five questions before booking

Do you routinely manage perimenopause and menopause?
Do you discuss both local and systemic FDA-approved options when appropriate?
Do you also use compounded products, and how do you decide when they are needed?
Do you take my insurance, and what is the full self-pay price if not?
How do follow-up, refills, lab orders, and messages between visits work?

What if I cannot get an appointment at all?

Answer capsule: Telehealth can solve a scope or wait-time problem, but the commercial model matters. Some services bill commercial insurance; others charge cash subscriptions. Medication and lab costs may sit outside the visit price. Some platforms offer both FDA-approved and compounded prescriptions, so confirm the exact product before paying rather than assuming the company name tells you what you will receive.

Disclosure: This section contains provider links. The HRT Index may earn a commission if you use an eligible link. Providers cannot pay for placement, a favorable conclusion, or removal of a verified limitation. Read the full affiliate disclosure.

Provider-stated access table

Verification method: The HRT Index checked each provider’s own pricing, insurance, lab, medication, and cancellation pages on August 26, 2026. This is document verification, not a firsthand care test. Prices and eligibility can change; confirm during intake or checkout.

Route	Published model	Published price	Medication and lab terms	Material limit	Best fit
Referral inside your current system	In-person or telehealth depending on the health system	Your plan’s specialist or primary-care cost	Depends on clinician, formulary, and plan	Wait time and local expertise vary	You want continuity, Medicare/Medicaid participation, or in-person evaluation
The Menopause Society directory	Free search, then book directly with the listed practice	Whatever the practice charges	Practice-specific	Not complete; listing is not a guarantee of fit	You want a menopause-focused local or telehealth shortlist
Midi Health	Telehealth in all 50 states; in-network with most PPO plans; self-pay available	$250 first visit; $150 follow-up	Visit price excludes labs and prescriptions. Core HRT pages describe FDA-approved estradiol and progesterone options; Midi also publishes separate compounded hormone products, so confirm the exact prescription.	Medicare is self-pay only with no claims to Medicare. Medicaid and Medi-Cal patients cannot be treated, even self-pay. Change or cancel a visit at least 24 hours ahead to avoid an unspecified cancellation fee.	You want an insurance-billed menopause specialist and your plan is accepted
Sesame menopause program	Cash-pay subscription; Sesame does not bill health insurance; video visits as needed and unlimited messaging	$59/month, provider-stated	Medication cost is not included. Basic CBC, A1c, thyroid, lipid, and metabolic labs are included if ordered, with direct-pay exceptions in NY, NJ, RI, and ND. The page lists FDA-approved options and says compounded BHRT may also be prescribed.	No first-month refund after the initial visit; cancel before the next billing cycle to avoid another charge. Clinician availability and prescribing depend on state and intake.	You want an ongoing cash-pay model and can price medications separately

Source: Midi pricing and insurance, Midi appointment-cost policy, Midi Medicare and Medicaid policy, Midi cancellation and rescheduling policy, and Sesame menopause treatment terms.

Midi’s honest negative—and who it routes away

Midi treats Medicare and Medicaid differently under its current policy.

Medicare: Midi permits self-pay, but neither Midi nor the patient can submit the claims to Medicare. Visits, labs, and medication are out of pocket.
Medicaid and Medi-Cal: Midi says it cannot treat these patients, even as self-pay.

If you have Medicaid or Medi-Cal, Midi is not your path. Full stop. Use your Medicaid or Medi-Cal plan directory, an in-network primary-care clinician or OB-GYN, or the referral route above.

If you have Medicare and can self-pay, the route remains open—but it is an out-of-pocket decision, not Medicare-covered care.

If you have a PPO plan, Midi is worth checking because it bills many commercial plans. “In network” does not mean free: deductibles, copays, coinsurance, labs, and prescriptions still vary by plan.

If your doctor’s answer was “I don’t manage this,” you do not need a better argument. You need a clinician who does.
→ Check Midi’s current coverage and self-pay terms

Sesame’s honest negative—and why the model still fits some women

Sesame’s current menopause offer is a $59 monthly subscription, not a one-off clinician-set visit price.

That buys access to the program, not the medication. Prescriptions cost extra. The included lab list is useful when the clinician orders those tests, but four states have payment exceptions. Once the first visit has happened, the first month is nonrefundable. You must cancel before the next billing cycle to avoid another charge.

The upside is a defined cash price, video visits as needed, messaging, and basic labs when ordered. The tradeoff is an ongoing subscription and separate medication cost.

Paying cash and want ongoing access instead of insurance billing?
→ See Sesame’s current menopause program and cancellation terms

FDA-approved and compounded are separate decisions

Some telehealth platforms offer both.

FDA-approved hormone products are reviewed by the FDA for safety, effectiveness, and manufacturing quality for their approved use. Compounded preparations are made for an individual prescription and are not FDA-approved before marketing. FDA says it does not have evidence that compounded “bioidentical” hormone products are safer or more effective than FDA-approved hormone therapy. (FDA menopause guidance)

That does not mean compounding never has a clinical role. It means the page, provider, and clinician must not blur the categories.

Before paying, ask:

What is the exact product name?
Is it FDA-approved or compounded?
Why is a compounded preparation needed instead of an approved option?
Which pharmacy makes it?
What will the medication cost after the visit or membership fee?
How are refills, dose changes, adverse effects, and cancellation handled?

Read the full compounded versus FDA-approved HRT guide.

What if estrogen is not appropriate for me?

Answer capsule: A contraindication to systemic estrogen is not the end of symptom treatment. FDA-approved nonhormonal options for moderate-to-severe hot flashes include fezolinetant and elinzanetant, but each has its own label restrictions and monitoring. Vaginal symptoms need a separate local-treatment discussion, and no local product should be assumed appropriate without checking the exact label and your history.

The two newer nonhormonal hot-flash drugs

Product	FDA-approved use	Current label points that matter
Veozah (fezolinetant)	Moderate-to-severe vasomotor symptoms due to menopause	NK3 antagonist; boxed warning for hepatotoxicity; liver tests before starting, monthly for the first 3 months, then at months 6 and 9; contraindicated with cirrhosis, severe renal impairment or end-stage renal disease, and CYP1A2 inhibitors
Lynkuet (elinzanetant)	Moderate-to-severe vasomotor symptoms due to menopause	NK1/NK3 antagonist; taken at bedtime; liver tests before starting and at 3 months; contraindicated in pregnancy; warnings include CNS depression/daytime impairment, hepatic transaminase elevation, pregnancy loss, and an August 2026 seizure-risk update

Source: Veozah current prescribing information and Lynkuet current prescribing information.

The current Lynkuet label requires more than a vague “less frequent monitoring” note: baseline liver testing, a 3-month follow-up test, bedtime dosing, daytime-impairment counseling, pregnancy restrictions, and the August 2026 seizure warning all belong in the decision.

Older nonhormonal options

The Menopause Society’s 2023 position statement supports several evidence-based nonhormonal approaches for vasomotor symptoms, including certain SSRIs and SNRIs, gabapentin, and other options selected around the individual patient. (2023 nonhormone therapy position statement)

“Nonhormonal” does not mean second-rate. For a woman with a contraindication, medication interaction, or personal preference against hormones, it can be the better fit.

Local vaginal treatment is a separate conversation

If the main problems are vaginal dryness, burning, painful sex, or recurring urinary symptoms, the treatment target is local tissue—not necessarily whole-body symptoms.

Low-dose vaginal estrogen, vaginal DHEA, ospemifene, moisturizers, lubricants, pelvic-floor care, and other options do not all have the same exposure, label, indication, or risk discussion. Some vaginal products are systemic. Ask about the exact product, not “vaginal hormones” as one category.

Use the vaginal estrogen guide for that conversation.

The coverage catch

The UnitedHealthcare commercial policy checked for this page requires documentation of a 30-day failure, contraindication, or intolerance to either hormone therapy or an older nonhormonal option before approving Lynkuet or Veozah, plus baseline liver testing.

Your plan may use different rules. The move is the same:

“What documentation will my insurer need, and can we put the contraindication, intolerance, or prior treatment in the chart today?”

If estrogen is off the table, that is an answer—not the end.
→ Find the HRT or nonhormonal starting path that fits my history

When to skip the script and get seen now

Answer capsule: This page prepares you for a nonurgent appointment. It is not a substitute for evaluation. Bleeding after menopause, new or unusually heavy bleeding, possible pregnancy, severe rapidly worsening symptoms, chest pain, severe shortness of breath, fainting, stroke symptoms, or thoughts of self-harm need prompt or emergency assessment rather than a conversation strategy.

Get evaluated promptly for

Any bleeding after menopause.
Bleeding that is new, unexplained, unusually heavy, prolonged, or after sex.
Possible pregnancy.
Severe symptoms that are worsening quickly.
A symptom your clinician has already said needs an exam, imaging, or testing.

Get emergency help for

Chest pain.
Severe shortness of breath.
Fainting.
Sudden one-sided weakness or numbness.
New trouble speaking or understanding speech.
A sudden severe headache with neurologic symptoms.
Thoughts of harming yourself.

Do not use a script, a telehealth signup, or a provider search to postpone something that needs urgent assessment.

What should I ask before I agree to an HRT plan?

Answer capsule: Before agreeing, confirm the target symptom, whether treatment is systemic or local, the exact product and route, whether it is FDA-approved or compounded, how the uterine lining is protected when relevant, the risks for your history, expected side effects and bleeding, medication cost, pharmacy access, what should trigger an early call, and the review date.

If the answer is yes, the conversation is not over. It has finally become specific.

Ask:

What symptom are we treating?
What would success look like, and by when?
Is this systemic or local?
Why this route—pill, patch, gel, spray, ring, cream, or insert—for me?
If I have a uterus, how is the uterine lining being protected?
What is the exact product name?
Is this exact product FDA-approved or compounded?
What are the most important risks and interactions for my history and medicines?
What side effects or bleeding might occur early?
What should make me stop, call, or seek urgent care?
Are labs required before or after starting?
What will the visit, labs, and medication each cost?
Is the product currently available at my pharmacy?
When do we review the result, and what would make us change the dose, route, or treatment?

Add one more when cost matters:

“Is there an FDA-approved generic that treats the same target and costs less on my formulary?”

Ask before leaving, not after the pharmacy rejects or prices the prescription.

What happens after I start?

Answer capsule: Starting hormone therapy is a monitored trial, not the end of the decision. Confirm how to use the exact product, what side effects and bleeding patterns to expect, how to reach the clinician, when benefits will be assessed, when labs are required, and what would trigger a dose, route, or treatment change. Track the target symptom—not every sensation.

Before the first dose, make sure you know:

How and when to use the medicine.
What to do after a missed dose.
Which common side effects may settle and which require a call.
What bleeding is expected for the regimen and what bleeding needs evaluation.
Which medicines, supplements, foods, or products may interact.
When any baseline or follow-up labs occur.
How refills work.
How to contact the clinician between visits.
The exact review date.

Then track the goal:

How often is the target symptom happening?
Is it still taking sleep, work, sex, or daily function from you?
Are you taking the medicine as directed?
Have side effects or bleeding appeared?
Has another clinician added a medicine or diagnosis?

There is no single follow-up schedule that fits every product and patient. Ask for your date.

A pharmacy problem to plan for in 2026

Estradiol patch supply remains product- and manufacturer-specific. ASHP’s current shortage page lists some strengths and manufacturers on back order or allocation while other patches remain available. Do not treat “estradiol patch shortage” as meaning every patch is unavailable. (ASHP shortage detail)

Ask before leaving:

“If this exact patch is unavailable, may the pharmacist substitute another equivalent product, or should they contact you first?”

How we verified this page

Answer capsule: The HRT Index Editorial Team built this guide from current FDA product labels and communications, The Menopause Society’s position statements and directory, NIH diagnostic guidance, peer-reviewed literature, current nonhormonal drug labels, a published payer policy, and provider-owned pricing and policy pages. It was not medically reviewed by a clinician and does not decide whether HRT is appropriate for any individual.

What we actually verified

FDA’s February 12, 2026 relabeling announcement and the current six-product list.
February 2026 FDA labels for Divigel and Bijuva, including boxed-warning changes and current contraindications.
The Menopause Society’s November 10, 2025 response to the FDA initiative.
The 2022 hormone therapy and 2023 nonhormone therapy position statements.
NIH’s menopause diagnostic overview, updated June 2026.
The peer-reviewed 2019 resident-training survey, including its 26% response rate.
The Menopause Society’s report on a 2025 annual-meeting presentation, labeled throughout as conference evidence rather than a peer-reviewed publication.
Current DailyMed labels for Veozah and Lynkuet, including Lynkuet’s August 2026 seizure warning.
UnitedHealthcare’s commercial prior-authorization policy effective May 15, 2026.
The Menopause Society directory and MSCP credential requirements.
Midi and Sesame pricing, insurance, lab, medication, Medicare/Medicaid, cancellation, and refund terms on August 26, 2026.
Current ASHP estradiol transdermal-system shortage details.

What we did not do

We did not consult a clinician for this page, and it was not medically reviewed.
We did not test a provider as a patient.
We did not review medical records.
We did not diagnose, determine eligibility, recommend a dose, or tell anyone to start, stop, or change treatment.
We did not use public forums as medical evidence.
We did not assign providers a numeric score.

The HRT Index Verification Standard is the documented process used to evaluate providers across five pillars, in this order: clinical legitimacy, care quality, medication fit, price transparency, access. For commercial facts, we read the provider’s published terms, separate FDA-approved from compounded, verify insurance and state access where published, date the check, and recheck top providers monthly and the wider roster quarterly.

Frequently asked questions

Can I just ask my doctor for HRT?

Yes. Ask for a discussion of whether hormone therapy fits your symptoms and history, not a guaranteed prescription. A good appointment can end in treatment, evaluation, an alternative, or a referral. Three of those four outcomes do not require a yes that day.

What do I say if I am nervous?

Use the 15-second line:

“I want to use today to decide whether hormone therapy fits my symptoms and history. If it doesn’t, I want to understand why and what the next best option is.”

Bring the one-page matrix so you do not have to hold the entire conversation in your head.

Can I ask about HRT if I am still having periods?

Yes. Perimenopause happens before the final period. Your clinician will also need your bleeding pattern, pregnancy possibility, contraception needs, and anatomy because those can change the regimen.

Do I need hot flashes to be considered?

No. Tell the clinician the symptoms you actually have. Vaginal and urinary symptoms often point toward local treatment; hot flashes and night sweats point toward vasomotor treatment; other symptoms may require a broader evaluation. Inventing hot flashes can send the plan toward the wrong target.

Do I need a blood test first?

Not always. Age, symptoms, and menstrual history are often enough for a typical transition. Testing is more useful when symptoms begin early, the pattern is atypical, pregnancy or another diagnosis is possible, cycles cannot be interpreted, or the chosen medication requires monitoring.

Can my regular doctor prescribe HRT, or do I need an OB-GYN?

A physician, nurse practitioner, physician assistant, or certified nurse-midwife may be able to prescribe when licensed and practicing within state scope and practice rules. Experience varies. Ask whether the clinician routinely manages menopause. If not, request a referral rather than treating that scope limit as a medical verdict.

Should I ask for the patch specifically?

Ask the clinician to compare routes. Observational evidence suggests transdermal estrogen may have a lower venous-clot risk than oral estrogen, but direct randomized comparisons are limited. “The patch is always safest” is stronger than the evidence and ignores skin reactions, supply, cost, dose, adherence, and your history.

Do I need progesterone if I have a uterus?

If you have an intact uterus and use systemic estrogen, endometrial protection generally belongs in the plan. The exact progestogen, schedule, or approved combination depends on the product. Ask what protects the lining in your prescription.

Is vaginal estrogen the same as systemic HRT?

No. Low-dose local vaginal therapy targets vaginal and urinary tissues and generally produces less systemic exposure than systemic therapy. Some vaginal products are systemic, and labels differ. Ask for the exact product rather than relying on the word “vaginal.”

What if I have a family history of breast cancer?

Bring the exact family history and any genetic-testing information. Family history is not listed as a contraindication in the current Divigel or Bijuva labels, but it can change risk assessment, screening, counseling, and whether specialist input is useful.

Do I still need birth control?

Possibly. Pregnancy can occur during perimenopause even when cycles are irregular. Menopausal hormone therapy is not contraception. Discuss a separate contraceptive plan until menopause is confirmed or your clinician says contraception is no longer needed.

Is it too late if I am over 60?

Not automatically. Starting systemic therapy after 60 or more than 10 years from menopause onset generally has a less favorable benefit-risk balance and needs individual assessment. Ask which symptom is being treated, what your absolute risks are, and which local or nonhormonal options remain.

Can I ask about testosterone?

Yes—but know the boundary. No testosterone product is FDA-approved specifically for women’s menopausal symptoms in the United States. Prescribing for women is off-label, and testosterone is a Schedule III controlled substance, so a prescription, state-compliant controlled-substance process, and clinical monitoring are required. The international consensus statement identifies the only evidence-based indication as carefully assessed hypoactive sexual desire disorder in postmenopausal women—not general fatigue, mood, muscle, cognition, or “optimization.” (Schedule III regulation; global consensus statement)

What if I want compounded “bioidentical” hormones?

Ask whether an FDA-approved option can meet the treatment goal first. Compounded preparations are not FDA-approved before marketing and should not be presented as automatically safer, more natural, more precise, or equivalent to an approved product. A clinician declining to prescribe compounded hormones may be taking an evidence-based position, not dismissing you.

Did the FDA remove the black box warning from HRT?

The FDA approved product-specific changes for six products on February 12, 2026. It was not a completed class-wide removal. Ask which exact product is being considered and read that product’s current label.

Will insurance cover HRT?

Coverage depends on the plan, product, pharmacy, diagnosis, and prior-authorization rules. Ask for the exact product and an FDA-approved generic when one fits, then check the formulary. Newer nonhormonal products may require proof that another treatment failed, was not tolerated, or was contraindicated.

What if my doctor refuses?

Ask for the specific reason, what would change the answer, what alternative treats the same symptom, and whether menopause care is outside the clinician’s scope. Ask for the reason and next step in your visit summary. Respect a real safety contraindication. Treat a scope no as a referral problem, not proof that your symptoms do not deserve care.

Still not sure which HRT program is right for you?

Take The HRT Index’s free Find My HRT Path quiz. It takes about 90 seconds, does not require email, separates FDA-approved and compounded options, and flags when an in-person clinician is the better starting point.

→ Find my best-fit HRT care path

Educational research only — not medical advice, diagnosis, or a substitute for care from a licensed clinician. Do not start, stop, or change hormone therapy without clinical guidance.

Sources

Choose the next HRT care route

See whether primary care can prescribe HRT, compare who can prescribe HRT, read what to do when your doctor says no, review online HRT providers, or use Find My HRT Path before booking.

Keep reading: